Psychiatric and cognitive function in patients with Neuroendocrine tumours with carcinoid syndrome.
- Conditions
- cognitieve stoornissencognitive impairmentdepression10027946
- Registration Number
- NL-OMON45631
- Lead Sponsor
- ederlands Kanker Instituut
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 85
- Patients with ileal NET with metastatic disease, diagnosed between 2012 and 2017
- Signed informed consent
- No sufficient understanding of the Dutch language.
- A previous cerebro vascular accident (assessed through review of the chart and checked with the patient)
- Severe cognitive problems such as a dementia.
- Delirium in the past 3 months
- Use of 5-HT modulating medication, such as SSRIs or SNRIs, or tryptophan
- Current chemotherapy, or chemotherapy in the past 5 years
- Previous malignancy in the past 5 years, except for adequately treated basal cell carcinoma of the skin.
- Life expectancy shorter than 3 months
- Patients with a primary psychotic disorder (schizophrenia)
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>To assess the severity of cognitive dysfunction and depressive symptoms in<br /><br>ileal NET patients and to relate this to peripheral 5-HT production. </p><br>
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.